No Data
No Data
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients With Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American...
Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
Kazia Therapeutics Advances Cancer Treatment Options
Kazia Therapeutics Enters Into Licensing Agreement With QIMR Berghofer
Express News | Kazia Therapeutics Ltd - Receives Exclusive Worldwide License for Pi3K Inhibitor Combinations
Express News | Kazia Executes Licensing Agreement With Qimr Berghofer